Atorvastatin Calcium Tablets Recalled for Manufacturing Quality Violations
Northwind Pharmaceuticals is recalling 99 bottles of Atorvastatin Calcium 10 mg tablets nationally due to manufacturing process deviations identified in March 2023.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall for manufacturing process deviations without reported illnesses or injuries. CGMP violations in the absence of confirmed harm represent precautionary recalls, which the rubric identifies as Moderate (score 2).
Plain-English summary
Northwind Pharmaceuticals LLC is voluntarily recalling Atorvastatin Calcium Tablets, USP 10 mg in 30-count bottles due to Current Good Manufacturing Practice (CGMP) deviations. The affected product is identified as NDC 51655-946-52, Lot # F117192201, with an expiration date of April 30, 2023. A total of 99 bottles were distributed nationwide across the United States.
The company initiated the recall on March 16, 2023. The FDA classified the recall as Class II. Northwind notified customers through email, fax, letter, press release, telephone, and in-person visits.
Consumers who have this medication should contact their pharmacist or healthcare provider about the recall. Patients should not stop taking atorvastatin without consulting their doctor, as the medication is essential for managing cholesterol levels. A healthcare provider can verify whether a patient's supply is affected and determine appropriate next steps.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Northwind Pharmaceuticals LLC
- Category
- Drug
- Hazard
- Affected units
- 99
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # F117192201
- Exp. Date 4/30/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 7 recalled by Northwind Pharmaceuticals LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin 10 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 40 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 80 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 20 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same manufacturer · Northwind Pharmaceuticals LLC
See all →- ModerateDouble strength antibiotic bottles recalled over micro-organism on packaging coil
FDA (Drugs) · 2025-09-24
- ModerateFDA Recalls Glimepiride Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- HighPrescription drug recall for manufacturing quality control deviations
FDA (Drugs) · 2023-05-03
- ModerateDrug Recall: Buspirone Tablets Over Manufacturing Process Deviations
FDA (Drugs) · 2023-05-03
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19